Claims for Patent: 9,056,126

Summary for Patent: 9,056,126

Title:	Hydrogel formulations
Abstract:	A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety.
Inventor(s):	Hersel; Ulrich (Heidelberg/Hanschuhsheim, DE), Rau; Harald (Heidelberg, DE), Schnepf; Robert (Heidelberg/Dossenheim, DE), Vetter; Dirk (Heidelberg/Neuenheim, DE), Wegge; Thomas (Heidelberg/Ziegelhausen, DE)
Assignee:	ASCENDIS PHARMA A/S (Hellerup, DK)
Application Number:	13/111,777
Patent Claims:	1. A mesoporous hydrogel-biologically active moiety conjugate prepared by a process comprising the steps of: synthesizing the mesoporous hydrogel, wherein the mesoporous hydrogel comprises backbone and crosslinking moieties, wherein each backbone moiety is linked with at least one other backbone moiety via several crosslinking moieties and wherein the crosslinking moieties comprise biodegradable bonds; and after completing all said synthesizing covalently connecting a prodrug linker to the mesoporous hydrogel which prodrug linker forms a reversible linkage to the biologically active moiety; and conjugating a biologically active moiety to the prodrug linker; wherein the connecting and the conjugating can be carried out in either order. 2. The mesoporous hydrogel-biologically active moiety conjugate of claim 1, wherein the prodrug linker has two functional groups, a first one of the two functional groups being complementary to a functional group attached to the mesoporous hydrogel and a second one of the two functional groups being conjugable to the biologically active moiety. 3. The mesoporous hydrogel-biologically active moiety conjugate of claim 2, wherein the first one of the two functional groups is selected from the group of functional groups consisting of carboxylic acid, amino, maleimide, thiol, sulfonic acid, carbonate, carbamate, hydroxyl, aldehyde, ketone, hydrazine, isocyanate, isothiocyanate, phosphoric acid, phosphonic acid, haloacetyl, alkyl halides, acryloyl, alpha-beta unsaturated michael acceptors, arylating agents, aryl fluorides, hydroxylamine, disulfides, vinyl sulfone, vinyl ketone, diazoalkanes, diazoacetyl compounds, epoxide, oxirane, and aziridine. 4. The mesoporous hydrogel-biologically active moiety conjugate of claim 2, wherein the first one of the two functional groups is selected from the group of functional groups consisting of thiol, maleimide, amino, carboxylic acid, carbonate, carbamate, aldehyde, and haloacetyl. 5. The mesoporous hydrogel-biologically active moiety conjugate of claim 2, wherein the first one of the two functional groups comprises a thiol or maleimide group. 6. The mesoporous hydrogel-biologically active moiety conjugate of claim 2, wherein the second one of the two functional groups is selected from the group of functional groups consisting of carboxylic acid, carbonate, hydroxyl, hydrazine, hydroxylamine, maleamic, ketone, amino, aldehyde, thiol and disulfide groups. 7. The mesoporous hydrogel-biologically active moiety conjugate of claim 2, wherein the biologically active moiety has a moiety functional group complimentary to the second one of the two functional groups. 8. The mesoporous hydrogel-biologically active moiety conjugate of claim 7, wherein the moiety functional group is selected from the group of functional groups consisting of thiol, carboxylic acid, amino, hydroxyl, ketone and imidazole. 9. The mesoporous hydrogel-biologically active moiety conjugate of claim 1, wherein the biologically active moiety comprises a biopolymer. 10. The mesoporous hydrogel-biologically active moiety conjugate of claim 1, wherein the biologically active moiety is selected from the group of proteins or polypeptides consisting of ACTH, adenosine deaminase, agalsidase, albumin, alpha-1 antitrypsin (AAT), alpha-1 proteinase inhibitor (API), alteplase, anistreplase, ancrod serine protease, antibodies (monoclonal or polyclonal, and fragments or fusions), antithrombin III, antitrypsins, aprotinin, asparaginases, biphalin, bone-morphogenic proteins, calcitonin (salmon), collagenase, DNase, endorphins, enfuvirtide, enkephalins, erythropoietins, factor VIla, factor III, factor VIlla, factor IX, fibrinolysin, fusion proteins, follicle-stimulating hormones, granulocyte colony stimulating factor (G-CSF), galactosidase, glucagon, glucocerebrosidase, granulocyte macrophage colony stimulating factor (GMCSF), phospholipase-activating protein (PLAP), gonadotropin chorionic (hCG), hemoglobins, hepatitis B vaccines, hirudin, hyaluronidases, idurnonidase, immune globulins, influenza vaccines, interleukins (1 alpha, 1 beta, 2, 3, 4, 6, 10, 11, 12), IL-1 receptor antagonist (rhIL-1ra), insulins, interferons (alpha 2a, alpha 2b, alpha 2c, beta 1a, beta 1b, gamma 1a, gamma 1b), keratinocyte growth factor (KGF), transforming growth factors, lactase, leuprolide, levothyroxine, luteinizing hormone, lyme vaccine, natriuretic peptide, pancrelipase, papain, parathyroid hormone, PDGF, pepsin, platelet activating factor acetylhydrolase (PAF-AH), prolactin, protein C, octreotide, secretin, sermorelin, superoxide dismutase (SOD), somatropins (growth hormone), somatostatin, streptokinase, sucrase, tetanus toxin fragment, tilactase, thrombins, thymosin, thyroid stimulating hormone, thyrotropin, tumor necrosis factor (TNF), TNF receptor-IgG Fc, tissue plasminogen activator (tPA), TSH, urate oxidase, urokinase, vaccines, and plant proteins. 11. The mesoporous hydrogel-biologically active moiety conjugate of claim 1, wherein the biologically active moiety comprises insulin. 12. The mesoporous hydrogel-biologically active moiety conjugate of claim 1, wherein the biologically active moiety comprises an organic small molecule bioactive agent. 13. The mesoporous hydrogel-biologically active moiety conjugate of claim 1, wherein the biologically active moiety is selected from the group of moieties consisting of central nervous system-active agents, anti-infective agents, anti-neoplastic agents, antibacterial agents, antifungal agents, analgesic agents, contraceptive agents, anti-inflammatory agents, steroidal agents, vasodilating agents, vasoconstricting agents, and cardiovascular agents with at least one primary or secondary amino group. 14. The mesoporous hydrogel-biologically active moiety conjugate of claim 1, wherein the biologically active moiety comprises an anti-sense or interfering nucleic acid. 15. The mesoporous hydrogel-biologically active moiety conjugate of claim 1, wherein the hydrogel is synthesized from the group of polymers consisting of polyalkyloxy-based polymers, dextran, chitosan, hyaluronic acid and derivatives, alginate, xylan, mannan, carrageenan, agarose, cellulose, starch, hydroxyethyl starch (HES) and other carbohydrate-based polymers, poly(vinyl alcohols), poly(oxazolines), poly(anhydrides), poly(ortho esters), poly(carbonates), poly(urethanes), poly(acrylic acids), poly(acrylamides), poly(acrylates), poly(methacrylates), poly(organophosphazenes), poly(siloxanes), poly(vinylpyrrolidone), poly(cyanoacrylates), poly(esters), poly(lactic acid), poly(glycolic acids), poly(iminocarbonates), poly(amino acids), collagen, and gelatin. 16. The mesoporous hydrogel-biologically active moiety conjugate of claim 1, wherein the hydrogel comprises polyacrylamide or a derivative thereof. 17. The mesoporous hydrogel-biologically active moiety conjugate of claim 1, wherein the hydrogel comprises poly(ethylene glycol acrylamide) or a derivative thereof. 18. The mesoporous hydrogel-biologically active moiety conjugate of claim 1, wherein the hydrogel is functionalized with a functional group selected from the group of reactive functional groups consisting of carboxylic acid, amino, maleimide, thiol, sulfonic acid, carbonate, carbamate, hydroxyl, aldehyde, ketone, hydrazine, isocyanate, isothiocyanate, phosphoric acid, phosphonic acid, haloacetyl, alkyl halides, acryloyl and other alpha-beta unsaturated michael acceptors, arylating agents like aryl fluorides, hydroxylamine, disulfides like pyridyl disulfide, vinyl sulfone, vinyl ketone, diazoalkanes, diazoacetyl compounds, epoxide, oxirane, and aziridine. 19. The mesoporous hydrogel-biologically active moiety conjugate of claim 1, wherein the hydrogel is functionalized with a functional group selected from the group of functional groups consisting of thiol, maleimide, amino, carboxylic acid, carbonate, carbamate, aldehyde, and haloacetyl. 20. The mesoporous hydrogel-biologically active moiety conjugate of claim 1, wherein the hydrogel is functionalized with maleimide. 21. The mesoporous hydrogel-biologically active moiety conjugate of claim 1, wherein the prodrug linker is attached to a non-degradable backbone of the mesoporous hydrogel. 22. The mesoporous hydrogel-biologically active moiety conjugate of claim 1 wherein the biodegradable bonds are selected from the group of chemically-cleavable bonds consisting of phosphate, phosphonate, carbonate, carbamate, disulfide and ester bonds. 23. The mesoporous hydrogel-biologically active moiety conjugate of claim 1, wherein the biodegradable bonds are enzymatically cleavable.

Details for Patent 9,056,126

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	01/15/1974		2024-07-05
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	12/27/1984		2024-07-05
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/15/1985		2024-07-05
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	02/16/1990		2024-07-05
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	03/26/1974		2024-07-05
Ferring Pharmaceuticals Inc.	A.P.L.	chorionic gonadotropin	For Injection	017055	12/13/1974		2024-07-05
Fresenius Kabi Usa, Llc	CHORIONIC GONADOTROPIN	chorionic gonadotropin	For Injection	017067	03/05/1973		2024-07-05